GlobeNewswire

Alethio Therapeutics Raises $90 Million (£67 Million) in Oversubscribed Series A Financing to Advance a New Generation of Therapies for Myeloproliferative Neoplasms
05/11/2026
Series A financing co-led by Sofinnova Partners and RA Capital alongside founding investor Oxford Science Enterprises with support from Cancer Research Horizons and the University of Oxford, bringing together a world- [...]
ArrayPatch Completes Oversubscribed €3.2 Million Seed Financing to Advance Next-Generation Microneedle Therapeutics
05/11/2026
CORK, Ireland, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, today announced the successful completion of the second close of [...]
ArrayPatch boucle un tour de financement d’amorçage sursouscrit de 3,2 millions d’euros pour faire progresser ses traitements par micro-aiguilles de nouvelle génération
05/11/2026
CORK, Irlande, 05 nov. 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (« ArrayPatch »), une société de biotechnologie développant des traitements novateurs à base de micro-aiguilles, a annoncé aujourd’hui la clôture réussie de [...]
Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease
05/11/2026
Completion of key IND-enabling activities represents a major development milestone for LB001 IND submission remains on track for Q1 2027, followed by initiation of a Phase 1/2 clinical study Manufacturing scale-up [...]
CurePSP Names First Recipients of Biomarker Accelerator Program, Awarding Its Largest Research Grants to Date
05/11/2026
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CurePSP has awarded more than $1.4 million through its Biomarker Accelerator Program to three researchers working to find reliable biomarkers for progressive supranuclear [...]
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
05/11/2026
Ghent, Belgium – November 5, 2026 , Nov. 05, 2026 (GLOBE NEWSWIRE) -- MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines Collaboration [...]
Resalis Therapeutics Announces First-in-Human Data for RES-010 Demonstrating Safety and Tolerability with Early Weight Loss Signals
05/11/2026
The completed Phase 1a study data in healthy volunteers showed early signs of pharmacodynamic activity supporting further clinical evaluation of RES-010 The Phase 1b study in healthy overweight and moderately obese [...]
Interim Report Q3 2026: Successful product launches leading to 2% organic revenue growth and margin expansion
05/11/2026
Highlights The Enterprise division delivered organic revenue growth of 1%, following positive market reception of the second wave of the Evolve3 launch. The development reflects continued solid performance in North [...]
Zelluna ASA: Third Quarter 2026 results
05/11/2026
Oslo, 5 November 2026 – Zelluna (OSE: ZLNA), a clinical-stage company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents [...]
IBA signe un contrat avec le gouvernement de l’État de l’Assam pour le premier centre public de protonthérapie en Inde
05/11/2026
Ce projet marque une étape importante pour élargir l’accès aux traitements de pointe contre le cancer en Inde Louvain-la-Neuve, Belgique, le 5 novembre 2026, 7h00 CET – IBA (Ion Beam Applications S.A., EURONEXT), leader [...]
IBA signs contract with the Government of Assam for India’s First State-run Proton Therapy Center
05/11/2026
The project in Assam marks an important milestone in expanding access to advanced cancer care in India Louvain-La-Neuve, Belgium, November 05, 2026 at 7 a.m. CET – IBA (Ion Beam Applications S.A., EURONEXT), the world [...]
Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook
05/11/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook Männedorf, Switzerland, November [...]
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
05/11/2026
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update Ongoing negotiations with different parties towards securing a partnership or financing for the development of varoglutamstat in [...]
Siemens Healthineers to Rebrand In Vitro Diagnostics Business as Olyrian Diagnostics
05/11/2026
Siemens Healthineers announced today it has initiated the carve-out process for its in vitro diagnostics business Tarrytown, New York, USA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- The company is preparing its Diagnostics [...]
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business
05/11/2026
Egetis Therapeutics’ lead asset, EMCITATE ® , is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1 [...]
Interim report 9M 2026
05/11/2026
Strong Q3 sales leading to 9M at 7% organic sales growth and adj. EBITDA margin of 37.9%. 2026 outlook confirmed: 7-8% organic sales growth and adj. EBITDA margin at the higher end of the 37-38% range. Ester Baiget, [...]
T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
05/11/2026
$133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with additional new investments from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Samsara BioCapital, M- [...]
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
05/11/2026
ROCKVILLE, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, [...]
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
05/11/2026
— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval — — Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum